Highlights of This Issue 3717

SPECIAL FEATURES

CCR Translations

3719 Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks
John M.L. Ebos and Roberto Pili
See article p. 3961

CCR Perspectives in Drug Approval

3722 Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Statistics in Clinical Cancer Research

3731 Cure Models as a Useful Statistical Tool for Analyzing Survival
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

Molecular Pathways

3743 Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations
Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

3750 Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

3762 Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

3772 Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
Yu Sawada, Motoenobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

3780 FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

3791 Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paola dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman

CCR Drug Updates

3737 Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi and Pasi A. Jänne

HUMAN CANCER BIOLOGY

3762 Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

3772 Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
Yu Sawada, Motoenobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

3780 FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

3791 Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paola dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman

CCR Drug Updates

3737 Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target
Leena Gandhi and Pasi A. Jänne
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3803</td>
<td>Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas</td>
<td>Luigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor</td>
</tr>
<tr>
<td>3822</td>
<td>Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy</td>
<td>Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O'Sullivan, Daniel B. Longley, and David J.J. Waugh</td>
</tr>
<tr>
<td>3846</td>
<td>Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response</td>
<td>Harvey Wong, Edna F. Choo, Bruno Alcicke, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbatts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould</td>
</tr>
<tr>
<td>3856</td>
<td>Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206</td>
<td>Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson</td>
</tr>
<tr>
<td>3868</td>
<td>Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer</td>
<td>Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spilia, Jessica Alessandroni, Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong Yok Tsang, Jeffrey Schlom, and Claudia Palena</td>
</tr>
<tr>
<td>3880</td>
<td>Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression</td>
<td>Shui Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann</td>
</tr>
<tr>
<td>3901</td>
<td>Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy</td>
<td>Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath</td>
</tr>
<tr>
<td>3924</td>
<td>Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice</td>
<td>Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata</td>
</tr>
</tbody>
</table>
Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma

Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nemat, Didier Decaudin, François-Clément Bidard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival

Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier


Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients


See commentary p. 3719
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.